Vaxart, Inc. cash flow statement VXRT

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Vaxart, Inc. generated $7.7 million of cash from operations, up 117.2% from the year before. It spent $145,000 on capital expenditures. That left free cash flow of $7.6 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2015 Jun 30, 2015	FY 2014 Jun 30, 2014
Operating
Depreciation and amortization	5 -40.7%	9 -3.1%	9 +2.6%	9 +48.6%	6 +38.0%	4 +55.3%	3 -24.6%	4 +12.3%	3 +3103.0%	1 -54.2%	2 -20.0%
Stock-based compensation	6 -36.5%	8 -27.7%	12 -18.6%	14 +4.0%	14 +53.2%	9 +103.5%	4 +595.1%	1 +16.3%	1 -71.6%	2 +23.5%	2 -34.6%
Operating cash flow	33 +208.3%	8 +117.2%	-45 +36.5%	-70 +25.7%	-95 -58.4%	-60 -151.9%	-24 -81.4%	-13 +10.0%	-15	-10 -190.9%	-3 +76.3%
Investing
Capital expenditures	1 +354.8%	0 -73.8%	1 -70.4%	2 -80.5%	10 +86.2%	5 +321.7%	1 +43.9%	1 +20.2%	1 +253.5%	0 +0.0%	0 -90.0%
Investing cash flow	-19 -176.1%	17 +178.0%	-21 -148.5%	44 +315.3%	-20 +58.4%	-49 -3924.3%	-1 -43.5%	-1 -103.2%	26	-19 -92.1%	-10 -131.9%
Financing
Short-term debt repaid	—	—	—	—	—	—	—	—	0	—	—
Financing cash flow	4 +4712.9%	4 -92.5%	57 +271.1%	15 -12.7%	17 -86.1%	126 -9.0%	138 +766.6%	16 +1023.1%	-2	-0 -100.4%	27 +6800.0%
Change in cash
Effect of exchange rate	—	—	—	—	—	—	—	—	—	-8 -626.7%	2 +131.2%
Net change in cash	18 +453.8%	29 +400.1%	-10 +15.4%	-11 +88.5%	-98 -679.2%	17 -85.1%	113 +5511.1%	2	—	—	—
Free cash flow	32 +204.9%	8 +116.7%	-45 +37.3%	-72 +30.7%	-104 -60.6%	-65 -160.2%	-25 -79.1%	-14 +8.6%	-15	-10 -185.3%	-3 +77.2%
Per share
Free cash flow per share	—	0.03	—	—	—	—	—	—	—	-0.27 -152.9%	-0.11 +79.5%
Ratios
Free cash flow margin	17.63%	3.19%	-157.90%	-980.13%	-97,551.40%	-7,285.76%	-617.23%	-141.35%	-366.79%	-39.43%	-4.95%
Capital expenditures to revenue	0.47%	0.06%	1.93%	25.36%	8,972.90%	578.14%	30.23%	8.62%	17.00%	0.41%	0.15%
Stock-based compensation to revenue	3.13%	3.50%	40.07%	191.52%	12,698.13%	994.06%	107.71%	6.36%	12.96%	8.54%	2.47%
Cash conversion	1.13x	0.47x	—	—	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: VXRT (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: South San Francisco, CA
SEC filer status: Accelerated filer, Smaller reporting company
SEC CIK: 72444
Former names: Aviragen Therapeutics, Inc. (until Feb 15, 2018); Biota Pharmaceuticals, Inc. (until Apr 13, 2016); NABI BIOPHARMACEUTICALS (until Nov 8, 2012); NABI BIOPHARMACEUTICALS (until Jun 29, 2010); NABI /DE/ (until Feb 14, 2002)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.